The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor

Translational Oncology ◽

10.1016/j.tranon.2021.101338 ◽

2022 ◽

Vol 17 ◽

pp. 101338

Author(s):

Xinru Chen ◽

Xiangchan Hong ◽

Gang Chen ◽

Jinhui Xue ◽

Jie Huang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Alk Inhibitor ◽

Immune Inflammation

Download Full-text

The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer

Future Oncology ◽

10.2217/fon-2018-0027 ◽

2018 ◽

Vol 14 (18) ◽

pp. 1875-1882 ◽

Cited By ~ 3

Author(s):

Shirish M Gadgeel

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

First Line Treatment

Download Full-text

What is the optimal first-line treatment for advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer?

Journal of Thoracic Disease ◽

10.21037/jtd.2017.04.43 ◽

2017 ◽

Vol 9 (5) ◽

pp. E447-E450

Author(s):

Ikuo Sekine

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

First Line Treatment

Download Full-text

Abstract CT088: Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)

10.1158/1538-7445.am2016-ct088 ◽

2016 ◽

Cited By ~ 1

Author(s):

Christine M. Lovly ◽

Jeffrey R. Infante ◽

George R. Blumenschein ◽

Karen Reckamp ◽

Heather Wakelee ◽

...

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Alk Inhibitor

Download Full-text

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

BMC Cancer ◽

10.1186/s12885-017-3720-8 ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 9

Author(s):

Jianya Zhou ◽

Jing Zheng ◽

Xiaochen Zhang ◽

Jing Zhao ◽

Yanping Zhu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

First Line Treatment

Download Full-text

Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer

Clinical Drug Investigation ◽

10.1007/s40261-019-00880-8 ◽

2019 ◽

Vol 40 (2) ◽

pp. 183-189 ◽

Cited By ~ 3

Author(s):

Hongchao Li ◽

Lei Lai ◽

Bin Wu

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma

Download Full-text

Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitor Brigatinib [AP26113] in Patients (PTS) with Alk+ Non–Small Cell Lung Cancer (NSCLC) and Brain Metastases

Annals of Oncology ◽

10.1093/annonc/mdv128.06 ◽

2015 ◽

Vol 26 ◽

pp. i57 ◽

Cited By ~ 8

Author(s):

D. Kerstein ◽

S. Gettinger ◽

K. Gold ◽

C.J. Langer ◽

A.T. Shaw ◽

...

Keyword(s):

Lung Cancer ◽

Brain Metastases ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Alk Inhibitor

Download Full-text

Detection of Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement in Non-Small Cell Lung Cancer and Related Issues in ALK Inhibitor Therapy

Molecular Diagnosis & Therapy ◽

10.1007/bf03262202 ◽

2012 ◽

Vol 16 (3) ◽

pp. 143-150 ◽

Cited By ~ 22

Author(s):

Eunhee S. Yi ◽

Jin-Haeng Chung ◽

Kimary Kulig ◽

Keith M. Kerr

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Gene Rearrangement ◽

Small Cell ◽

Inhibitor Therapy ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Alk Inhibitor

Download Full-text

Model‐Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First‐Line Anaplastic Lymphoma Kinase + Non‐Small Cell Lung Cancer

Clinical Pharmacology & Therapeutics ◽

10.1002/cpt.1340 ◽

2019 ◽

Vol 105 (4) ◽

pp. 826-828

Author(s):

Peter N. Morcos ◽

Jiang Liu ◽

Gideon M. Blumenthal ◽

Hong Zhao

Keyword(s):

Lung Cancer ◽

Drug Development ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Development Approach

Download Full-text

Cost-Effectiveness of Crizotinib, Ceritinib, and Alectinib as First-Line Treatments for Anaplastic Lymphoma Kinase-Positive (ALK+) Metastatic Non-Small Cell Lung Cancer

Value in Health ◽

10.1016/j.jval.2018.04.208 ◽

2018 ◽

Vol 21 ◽

pp. S32-S33

Author(s):

S Xuan ◽

J Ma

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma

Download Full-text

P84.08 First-line Brigatinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer: A Network Meta-Analysis

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.01.1207 ◽

2021 ◽

Vol 16 (3) ◽

pp. S659-S660

Author(s):

H. Lin ◽

A. Cichewicz ◽

B. Neupane ◽

Y. Wu ◽

L. Vinals ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Meta Analysis ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma

Download Full-text